GL CAPITAL MANAGEMENT LIMITED

Thesis

GL Capital Management Limited is a private equity firm founded in 2010 and based in Beijing, China, with a dedicated focus on the healthcare sector. The firm's investment strategy involves identifying and investing in high-potential healthcare companies that possess long-term sustainable competitive advantages. GL Capital primarily targets buyout and significant minority investment opportunities within China's rapidly expanding healthcare industry. They emphasize close collaboration with management teams, acting as both strategic and financial partners to generate enduring value. Their investment expertise covers the full healthcare spectrum, including pharmaceuticals, biotechnology, medical devices, healthcare services, and contract research organizations (CROs). The firm is committed to ESG principles, integrating them into its operations and portfolio through a strategy focused on People, Planet, and Society, aligned with UN Sustainable Development Goals. As of August 30, 2025, GL Capital's AUM exceeded $3.9 billion, managing both USD and RMB funds. GL China Opportunities Fund V has a target of $800 million, aiming to surpass its predecessor, Fund IV ($482.5 million in 2023). Fund V is expected to concentrate on buyouts, whereas previous funds had a more balanced approach between buyouts and significant minority stakes. The firm's primary geographic focus is China. Specific check size details are not available. The firm also benefits from a strong advisory committee.